Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch & LombBLCO -1.07%77 EV-to-EBITDA is 14.67 as of Aug. 04, 2026, which is 19% below its 10-year median of 18.11. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.15 (Fairly Valued). The stock has 9 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Bausch & Lomb ranks worse than 51.95% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bausch & Lomb's enterprise value is $10,781 Mil.
Bausch & Lomb's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $735 Mil. Therefore, Bausch & Lomb's EV-to-EBITDA for today is 14.67.
The historical rank and industry rank for Bausch & Lomb's EV-to-EBITDA or its related term are showing as below:
BLCO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.36 Med: 18.11 Max: 22.12
Current: 14.67
During the past 8 years, the highest EV-to-EBITDA of Bausch & Lomb was 22.12. The lowest was 10.36. And the median was 18.11.
BLCO's EV-to-EBITDA is ranked worse than 51.95% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.44
vs BLCO: 14.67
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bausch & Lomb's PE Ratio (TTM) for today is calculated as:
Bausch & Lomb's share price for today is $16.59.
Bausch & Lomb's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.480.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Bausch & Lomb's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's EV-to-EBITDA falls into.
Bausch & Lomb's current Enterprise Value is $10,781 Mil.
Bausch & Lomb's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $735 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a EV-to-EBITDA of 14.67 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bausch & Lomb. This is 19% below median its historical median of 18.11. Over the past decade, Bausch & Lomb's EV-to-EBITDA has ranged from 10.36 to 22.12. According to the industry distribution chart, Bausch & Lomb ranks #266 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 52%.
Is Bausch & Lomb's EV-to-EBITDA too high?
Bausch & Lomb's current EV-to-EBITDA of 14.67 is 19% below median its 10-year median of 18.11. Over the past 10 years, this metric has ranged from a low of 10.36 to a high of 22.12. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.44. Bausch & Lomb's value of 14.67 is 1.6% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #266 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #266 out of 512 companies for EV-to-EBITDA. This places Bausch & Lomb in the lower half of its industry. The industry median EV-to-EBITDA is 14.44. Bausch & Lomb's value of 14.67 is 1.6% above this benchmark. Historically, Bausch & Lomb's own EV-to-EBITDA has ranged from 10.36 to 22.12 over the past decade. While the company's 10-year median is 18.11 vs. the industry median of 14.44, Bausch & Lomb has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.44, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current EV-to-EBITDA of 14.67 is 1.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Bausch & Lomb. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current EV-to-EBITDA is 14.67, which is 19% below median its own 10-year median of 18.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Fairly Valued. The stock's GF Value™ is $18.15, compared to a current price of $16.59 — trading 8.6% below its estimated fair value. The current EV-to-EBITDA is 14.67, which is 19% below median its 10-year median of 18.11 and 1.6% above the Medical Devices & Instruments industry median of 14.44. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current EV-to-EBITDA is 14.67 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $16.59 is trading 8.6% below its estimated GF Value™ of $18.15.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for BLCO:
EV-to-EBITDA: 14.67 (19% below median its 10-year median of 18.11)
GF Value™: $18.15 vs. price of $16.59 (8.6% below fair value)
Industry Position: 1.6% above the Medical Devices & Instruments median (#266 of 512)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 
